Small-Cap Stocks Extend Momentum in After-Hours Trading

Adaptimmune Therapeutics surged 30% to $0.2020 in after-hours trading, following a 98% gain in the regular session. Butterfly Network extended its rally, climbing 10.58% to $2.09 after a 15.95% gain in the regular session. Aquestive Therapeutics rose 7.69% to $5.32 after a 2.28% gain in the regular session. The gains are driven by renewed investor interest and recent strategic updates, leadership moves, and pipeline developments.

Butterfly Network (BFLY) and Omnicell (OMCL) have been standout performers in the health technology sector, driven by recent strategic updates and technological advancements. Both companies have seen significant gains in their stock prices, with Butterfly Network surging 30% and Omnicell rising 10.58% after a 15.95% gain in the regular session.

Butterfly Network, known for its innovative AI-driven diagnostic imaging solutions, reported impressive results in August 2025. Its iQ+ handheld ultrasound paired with a machine learning model achieved high accuracy (AUROC of 0.94) in detecting aortic stenosis, a condition often underdiagnosed. The company also launched the "Aorta Exam" protocol through its ScanLab AI-powered training app, enhancing clinician skills in using handheld ultrasound. Additionally, Butterfly Network is involved in the international research study CAD LUS4TB, evaluating AI-assisted point-of-care ultrasound for tuberculosis triage in under-resourced settings The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM^[1].

Omnicell, which focuses on medication management solutions, has been pushing forward its technology roadmap. In 2025, the company opened an Innovation Lab in Austin, TX, dedicated to creating solutions across the medication journey, including advanced robotics, AI, autonomous devices, sensor tech, and machine vision. It introduced product lines like MedTrack, an RFID-enabled drawer for tracking medications, and MedVision, a web-enabled software for real-time inventory visibility and automated reordering. These technologies aim to reduce manual tasks, improve safety, and increase efficiency in medication management workflows The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM^[1].

The growth in the health technology sector is driven by the increasing demand for AI-enabled diagnostics, imaging, drug discovery, clinical workflow automation, and remote patient monitoring. According to a Fortune Business Insights report, the global AI in healthcare market is projected to scale from $39.25 billion in 2025 to approximately $504.17 billion by 2032, at a CAGR of 44.0% The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM^[1].

Big tech players, such as NVIDIA and Palantir, are also aggressively positioning themselves in the healthcare sector. NVIDIA's collaboration with IQVIA leverages agentic AI to automate complex workflows across clinical research and life sciences, while Palantir's partnership with TeleTracking uses its AIP tools to optimize staffing workflows and improve patient-centered care operations The Zacks Analyst Blog Highlights Butterfly Network, Omnicell, NVIDIA, Palantir and IBM^[1].

The strategic moves and technological advancements by Butterfly Network and Omnicell, along with the broader growth trends in the health technology sector, have driven renewed investor interest in these companies. As the sector continues to evolve, these stocks are likely to remain attractive to investors seeking exposure to the transformative trend of AI in healthcare.